1,1-dimethylethyl 4-[({4-bromo-2-[(methyloxy)carbonyl]phenyl} oxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate | 1165946-35-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-dimethylethyl 4-[({4-bromo-2-[(methyloxy)carbonyl]phenyl} oxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• 英文别名: 1,1-Dimethylethyl 4-[({4-bromo-2-[(methyloxy)carbonyl]phenyl}oxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate；tert-butyl 4-[(4-bromo-2-methoxycarbonylphenoxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 1165946-35-9
• 化学式: C₁₉H₂₆BrNO₆
• 分子量: 444.323
• InChiKey: AXAITDDISPCGKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  74.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 4-[({4-bromo-2-[(methyloxy)carbonyl]phenyl} oxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 在 四(三苯基膦)钯 、 硼烷四氢呋喃络合物 、 碳酸氢钠 、 对甲苯磺酸 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 30.0h， 生成 1,1-dimethylethyl 7-cyano-3-(hydroxymethyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336
• 作为产物：
  描述：

  5-溴水杨酸甲酯 、 tert-butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 甲苯 为溶剂， 反应 18.0h， 以57%的产率得到1,1-dimethylethyl 4-[({4-bromo-2-[(methyloxy)carbonyl]phenyl} oxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
  参考文献：
  名称：

  [EN] 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  [FR] COMPOSÉS DE 1,2,4-OXADIAZOLE POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES

  摘要：

  本发明涉及公式(I)的新型噁二唑衍生物或其药学上可接受的盐。公式(I)化合物及其药学上可接受的盐可用于治疗通过S1 P1受体介导的疾病或紊乱。特别是公式(I)化合物及其药学上可接受的盐可用于治疗多发性硬化症、自身免疫疾病、慢性炎症性疾病、哮喘、炎性神经病、关节炎、移植、克罗恩病、溃疡性结肠炎、红斑狼疮、银屑病、缺血再灌注损伤、实体肿瘤、肿瘤转移、与血管生成相关的疾病、血管疾病、疼痛症状、急性病毒性疾病、炎症性肠病、胰岛素依赖和非依赖性糖尿病。

  公开号：

  WO2009080730A1

文献信息

• 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：Heer Jag Paul

  公开号：US20100273770A1

  公开（公告）日：2010-10-28

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁唑二氮杂环衍生物，其制备过程，包含它们的制药组合物以及它们在治疗各种疾病中的应用。